Uh-oh, Xtandi. J&J nabbed an early approval for Erleada by Tracy Staton Wednesday, February 14, 2018 With an early approval for its new drug Erleada, J&J just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer.
Xtandi, apalutamide up for head-to-head fight in prostate cancer by Tracy Staton Tuesday, February 6, 2018 Pfizer, Astellas and J&J envision a wide-open field for patients whose prostate cancer hasn't spread. But there's a high-stakes market scrum ahead.
J&J's blockbuster Zytiga faces 2018 generic threat by Eric Sagonowsky Thursday, January 18, 2018 Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Astellas innovation contest yields creative cancer solutions by Beth Snyder Bulik Monday, October 30, 2017 Astellas Oncology's C3 competition featured an AI-powered companion robot and a healthcare professionals’ app to facilitate diagnosis and treatment.
It's time to force lower prices on Biogen MS drug: lawmaker by Eric Sagonowsky Friday, September 29, 2017 Rep. Elijah Cummings, D-Md., is urging President Trump to press for lower prices on Biogen's multiple sclerosis drug Zinbryta.
Astellas, Pfizer eye bigger Xtandi market as key trial scores by Tracy Staton Thursday, September 14, 2017 After Johnson & Johnson's Zytiga put up notable prostate cancer data, Astellas and Pfizer needed a win for their medicine Xtandi. Now they have one.
FiercePharmaAsia—GSK, Pfizer-Astellas, Daiichi Sankyo by Angus Liu Friday, August 4, 2017 GSK will close its Shanghai neuroscience R&D hub, Pfizer and Astellas stopped Xtandi's breast cancer study and more.
CVS formulary knocks Jardiance in favor of Invokana by Eric Sagonowsky Wednesday, August 2, 2017 Right on the heels of Express Scripts’ 2018 formulary release, rival PBM giant CVS Caremark has published its list of which drugs are in and which are out.
Sanders pushes for price limits on taxpayer-funded drugs by Eric Sagonowsky Tuesday, August 1, 2017 Sen. Bernie Sanders is moving in Congress to institute price restrictions on medical products created with U.S. taxpayer dollars.
Pfizer's Prevnar and Enbrel falter in Q2, raising doubts by Arlene Weintraub Tuesday, August 1, 2017 Pfizer announced mixed results in its second quarter, marked by a revenue shortfall on two aging blockbusters.
